Sign inJoin waitlistJoin the waitlist

KA

Kathryn Arbour

Assistant Attending Physician · New York Presbyterian Hospital

Credentials: · · · ·

History

New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
2014–2016
Internal Medicine
Weill Cornell Medicine
2011–2014
Weill Cornell Medicine
2007–2011

Research

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled…
Journal of Clinical Oncology · 2018 · 1,159 citations
Acquired Resistance to KRASG12C Inhibition in Cancer
New England Journal of Medicine · 2021 · 1,038 citations
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review
Review · JAMA · 2019 · First of 2 authors · 903 citations

GR
Gregory Riely
28 papers
MH
Matthew Hellmann
22 papers
ML
Marc Ladanyi
15 papers
MK
Mark Kris
15 papers
Charles Rudin
14 papers
AP
Andrew Plodkowski
13 papers
MA
Mark Awad
13 papers
Piro Lito
12 papers
HY
Helena Yu
11 papers
AS
Adam Schoenfeld
10 papers · 6 as a fellow
Biagio Ricciuti
9 papers · 7 as a resident
NR
Natasha Rekhtman
9 papers

Clinical trials

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2018–2022
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Principal investigator · Active not recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2017–2027
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Site PI · Recruiting · Phase 2
Verastem, Inc.
2026–2028
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2023–2031